RecruitingPhase 2NCT06633068

The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.

Sponsor

Cairo University

Enrollment

54 participants

Start Date

Jul 15, 2024

Study Type

INTERVENTIONAL

Conditions

Intra and Postoperative Pain Management

Summary

This study aiming to evaluate the analgesic effect of adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries regarding first rescue analgesia in the first twenty-four hours postoperative, VAS score after extubation and complications such as postoperative nausea, vomiting and respiratory depression.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria2

Patients aged between 18 to 60 years old of both sexes undergoing elective thyroid surgery.
ASA I and II.

Exclusion Criteria8

Patient refusal.
Hypersensitivity or contraindication to nalbuphine or bupivacaine.
Pregnancy or lactating mothers.
Hepatic, cardiac or renal diseases.
Bleeding disorders.
Severe neurological or psychological disorders.
Goitres with retrosternal extension.
Any anatomical disruption in the neck (ex: metastatic lymph nodes).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block

Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries

Locations(1)

Kasr Alainy Teaching Hospitals

Giza, الجيزة, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06633068